Pasithea TherapeuticsKTTA
Recorded

Pasithea Therapeutics KOL event

Review the key takeaways and the transcript of this earnings call.

Period 0Duration1 hr 7 minParticipants6

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good morning, everyone, and welcome to the Pasithea Therapeutics virtual KOL event. At this time, all attendees are in a listen-only mode, and a question-and-answer session with our key opinion leaders will follow after each formal presentation. As a reminder, this call is being recorded, and a replay will be made available on the Pasithea website following the conclusion of the event. I'd now like to turn the call over to Dr. Tiago Reis Marques, Chief Executive Officer at Pasithea Therapeutics.

Tiago Reis MarquesCEO

Please go ahead, Tiago. Good morning, and thank you for joining us.

Tiago Reis MarquesCEO

I'm Tiago Reis Marques, Chief Executive Officer of Pasithea Therapeutics. Over the next hour, we're going to talk about neurofibromatosis type 1, a genetic condition that is present in roughly one in 3,000 people and for which treatment options remain remarkably thin. Our lead candidate, PAS-004, is a next-generation macrocyclic MEK inhibitor designed for chronic dosing, once-daily treatment built to be taken chronically. We have three objectives today. First, to give you a clear picture of the two manifestations of NF1 we are developing PAS-004 for, plexiform neurofibromas and cutaneous neurofibromas, and we're going to hear from the clinicians who treat them every day. Second, to walk you through what we know about PAS-004 so far, the molecule, the phase I solid tumor data, and the design of our ongoing NF1 study.

Tiago Reis MarquesCEO

Third, to discuss the size and shape of the commercial opportunity. We'll have four speakers in this order. Kartik Krishnan, our Chief Medical Officer, will open with PAS-004 itself. Then Dr. Rebecca Brown from the University of Alabama at Birmingham. She'll cover plexiform neurofibromas. Then Dr. Kavita Sarin from Stanford will cover cutaneous neurofibromas. Finally, I'll close with the commercial opportunity. Just a quick note before we start, this presentation contains forward-looking statements, and the usual disclaimers apply.

Kartik KrishnanChief Medical Officer

Kartik, over to you. Thank you, Tiago, and thanks to everyone joining us today.

Kartik KrishnanChief Medical Officer

I'm Kartik Krishnan. I'm the Chief Medical Officer at Pasithea Therapeutics. Our program today is focused on the neurocutaneous manifestations of NF1. I would first like to take this opportunity to introduce our molecule, PAS-004, our novel inhibitor of the MEK protein kinase. I'll talk about the molecule, some recent data in advanced cancer patients that we presented at the European Society for Medical Oncology, or ESMO, in Madrid on October 23rd, and then lead into our key opinion leader experts in neurofibromatosis. It's important to understand that PAS-004 was not designed as an anti-cancer MEK. Rather, it is a macrocyclic structure. This macrocycle provides increased bioavailability and a longer half-life. In addition, PAS-004 has no reactive primary alcohols, potentially limiting the conversions into toxic metabolites.

Kartik KrishnanChief Medical Officer

The goal of the design of PAS-004 was to find the sweet spot between a robust activity, a low safety burden, and a convenient dosing regimen that allows patients to potentially stay on drug longer and appreciate the efficacy benefit of chronic dosing. First approval of MEK inhibitor was for trametinib as monotherapy for the treatment of BRAF V600E/K mutant metastatic melanoma back in 2013. As such, our first in-patient phase I clinical trial was begun in advanced cancer patients. I did just say that PAS-004 was not intended to be an anti-cancer MEK, but it is an inhibitor of the pathway that is critical in many cancers. Moreover, phase I clinical trials in cancer enroll very quickly at specialized centers that generate reliable data in such areas as PK.

Kartik KrishnanChief Medical Officer

In this phase I, we have been able to look at both a capsule formulation of raw API and a tablet formulation. Further, we have begun a pilot food effect study that will give us preliminary evidence on the optimal dosing strategy for PAS-004. PAS-004 is a once-daily dose, so taking it fasting first thing in the morning is fairly easy and routine, but understanding the food effect is good information to have. As with most phase I trials in recurrent metastatic advanced cancer, efficacy is limited. Nonetheless, when we look at the swim lanes that show the time from initiation of therapy to progression or continuation, we see that four of the 34 patients enrolled in this swim plot, three of the patients being too new, were on treatment for more than 300 days or 10 months.

Kartik KrishnanChief Medical Officer

If we look at the subset of patients who have BRAF V600E mutant, we see that two of these patients have been on for greater than 500 days, and in fact are continuing on therapy today. While the numbers are too small to provide a categorical conclusion, I can say that for at least these two patients with recurrent metastatic melanoma who had failed prior treatment with combination of BRAF and MEK inhibitors, there is a clinical benefit for that. When we look further at safety in these patients, we see that there were no dose-limiting toxicities, no grade 3 or grade 4 or 5 related adverse events. No discontinuations due to related adverse events, and low rates of rash and diarrhea, which are known toxicities of MEK inhibitors.

Kartik KrishnanChief Medical Officer

We have not done a formal exposure safety analysis that I can present here today, but I will say that the patients who were receiving PAS-004 for more than 300 days, including the two who were on for more than 500 days and continue, no rash or diarrhea has been reported. We believe the tolerability of PAS-004 is due, at least in part, to its pharmacokinetic properties. Looking at the day 22 samples, again, these are patients who have been on drug daily for three weeks, we see a very flat PK profile. The Cmin to Cmax ratio is less than 1.5, meaning that at steady state, PAS-004 is essentially maintained at the same level without a spike at Cmax or drop below the potentially therapeutic levels immediately prior to dosing. With a half-life of nearly 60 hours, once-daily dosing should be fairly easy and maintain compliance.

Kartik KrishnanChief Medical Officer

As you will hear from our experts, the neurofibromatosis type 1, or NF1, results from a loss of the mechanism that turns off the RAS signaling pathway. RAS in the GDP-bound form is inactive, whereas RAS in the GTP-bound form is active and signals to promote growth. RAS is turned off by a GTPase-activating protein, or a GAP, of which neurofibromin, or the gene mutated in NF1, is one. Loss of this GAP results in hyperactivation of the RAS pathway, and it is here that PAS-004 exerts its activity. Given what I have shown you in the previous slides on tolerability and long-term lack of toxicity, we believe that effective therapies in genetic conditions like RASopathies, like NF1, will be related to chronic suppression that is tamping down of the pathway rather than the total pathway shutdown that is for a brief period that is required for anti-cancer effect.

Kartik KrishnanChief Medical Officer

As such, we are evaluating PAS-004 in a phase I trial of neurofibromatosis type 1, looking at the effects of increasing MEK inhibitor doses on the neurocutaneous manifestations of NF1. Tiago will return to detail this evaluation, as well as the regulatory landscape and overall opportunity a little later. Before that, we will hear from Dr. Rebecca Brown and Dr. Kavita Sarin, two experts in the field of neurofibromatosis, who will share their knowledge of the biology, current treatment landscape, and unmet need experienced by patients with NF1. With that, I would like to introduce Dr. Rebecca Brown, who is Director of the Neurofibromatosis and Schwannomatosis Program at the University of Alabama at Birmingham.

Rebecca BrownDirector of the NF and Schwannomatosis Program

Dr. Brown? Thank you, Kartik.

Rebecca BrownDirector of the NF and Schwannomatosis Program

I am Dr. Rebecca Brown at the University of Alabama at Birmingham, and I am Director of the NF and Schwannomatosis Program. I wanted to introduce plexiform neurofibromas. The incidence of NF1 is approximately one in 2,500 people across the world, across all races and ethnicities, and approximately half of these individuals have a plexiform neurofibroma. The estimated U.S. impact based on the census in 2021 is approximately 137,000 individuals with NF1, of which 68,000 have a plexiform neurofibroma. Most of those plexiform neurofibromas are symptomatic, approximately three-quarters, or an estimate of 51,000 individuals.

Rebecca BrownDirector of the NF and Schwannomatosis Program

Of those individuals, only about 5% are on a MEK inhibitor, which is the class of drugs that is currently FDA approved for the treatment of plexiform neurofibromas, which leads to about 48,000 individuals in the United States alone who have an unmet need to be placed on plexiform neurofibroma treatment with MEK inhibitors, and I am going to talk about this a little bit later. Of note, approximately 13% of patients who do have a plexiform neurofibroma are at risk of a malignant sarcoma, which is almost entirely life-threatening, if not life-ending. To give a little bit of background about plexiform neurofibromas, they originate from a type of cell called neural crest cells.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day